On Demand 2023 Saturday PM General Sessions

This collection covers general sessions from Saturday's program. This includes plenaries, and symposia. The sessions listed below are included in this package:

  • Reimbursement for Technology Enabled Services
  • The Changing Landscape of Primary Immunodeficiency
  • 7 for 11 - Hot Topics in Pediatrics A&I - A Joint Presentation from AAP-SOAI & ACAAI
  • Challenging Symptoms to Manage in Rhinosinusitis / Airway Diseases
  • Climbing the Baked Egg/Milk Ladder: Is It As Safe As We Assume?
  • From Bleach Baths to Biologics: Evidence and Recommendations From the 2023 Atopic Dermatitis Parameters
  • Chronic Spontaneous Urticaria: Itching for the Latest Information

The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The American College of Allergy, Asthma & Immunology (ACAAI) designates this enduring material for a maximum of 11 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Target Audience

Medical professionals who treat patients with allergic and/or immunological conditions:

  • Practicing allergist/immunologists
  • Allergy/immunology Fellows-in-Training
  • Physician assistants
  • Nurses and advanced practice nurses
  • Allied health professionals
  • Primary care physicians
  • Other medical professionals

Learning Objectives

Upon completion of this session, participants should be able to:

  • Compare new diagnosis and treatments for food allergy.
  • Identify updates in pediatric asthma and allergy.
  • Recognize changes in diagnosis and management of pediatric skin and immune disorders.
  • List the medical and surgical treatments available for patients with recalcitrant rhinorrhea.
  • Describe the anatomic and medical treatments for and be able to offer practical treatment options to patients with severe nasal congestion.
  • List the differential diagnosis of smell impairment and medical/surgical approach to anosmia.
  • Formulate a diagnostic algorithm for patients presenting with chronic cough and discuss treatment options.
  • Indicate how to appropriately diagnose humoral immune deficiency beyond Ig levels and vaccine responses, including when to consider genetic testing.
  • Identify pulmonary complications associated with IEIs and discuss management strategies.
  • Discuss the emerging role of gene therapy for IEIs.
  • Explain current reimbursement and licensure laws for telemedicine.
  • Utilize reimbursement options and requirements for RPM and RTM.
  • Review other technology-based patient care services and reimbursement options for each.
  • Discuss the risks and benefits of dietary advancement therapies, such as milk and egg ladders.
  • Identify the right candidates for milk/egg ladders and describe patient instructions.
  • Describe risks and benefits of baked milk/egg OIT and identify unmet needs.
  • Implement strategies to improve guideline-directed use of second-generation antihistamines in the emergency department.
  • Comprehend the international guidelines for the management of patients with CSU, revisit current treatment recommendations and understand the burden of refractory disease.
  • Discuss therapeutics currently FDA-approved for other indications, now under investigation for treatment of CSU and ISM.
  • Review recent data on novel therapeutics under investigation for CSU and ISM.
Additional information

As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma and Immunology (ACAAI) policy, all individuals in a position to control or influence the content of an activity must disclose all financial relationships with any ineligible company that have occurred within the past 24 months. The ACCME defines a “ineligible company” as companies whose primary business is producing, marketing, selling, re-selling, or distributing health care goods or services, used by or on patients. Examples of such organizations include: 
•    Advertising, marketing, or communication firms whose clients are ineligible companies
•    Bio-medical startups that have begun a governmental regulatory approval process
•    Compounding pharmacies that manufacture proprietary compounds
•    Device manufacturers or distributors
•    Diagnostic labs that sell proprietary products
•    Growers, distributors, manufacturers or sellers of medical foods and dietary supplements
•    Manufacturers of health-related wearable products
•    Pharmaceutical companies or distributors
•    Pharmacy benefit managers
•    Reagent manufacturers or sellers
The ACCME does not consider providers of clinical service directly to patients to be commercial interests. For more information, visit www.accme.org. All identified relevant relationships must be mitigated and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure of or absence of relevant financial relationships be provided to the learners prior to the start of the activity.
Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials.
Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI. All identified relevant financial relationships have been mitigated.

Course summary
Available credit: 
  • 11.00 AMA PRA Category 1 Credit™
  • 11.00 Attendance
  • 11.00 CBRN
Course opens: 
Course expires: 

Travis A. Miller, MD, FACAAI
Farah N. Khan, MD
Sakina S. Bajowala, MD
Tania Elliott, MD, FACAAI
Jennifer A. Shih, MD, FACAAI
Sudhir Gupta, MD, PhD, FACAAI  
Jordan S. Orange, MD, PhD, FACAAI  
John Michael Routes, MD, FACAAI  
Jolan Walter, MD
Todd A. Mahr, MD, FACAAI
Angela Duff Hogan, MD, FACAAI
Theresa A. Bingemann, MD, FACAAI
J. Andrew Bird, MD, FACAAI
Eric M. Schauberger, DO, PHD, FACAAI, FAAAAI
Julie Wang, MD, FACAAI
Mary Beth Fasano, MD, MSPH, FACAAI
Ama Alexis, MD, FACAAI
Gerald B. Lee, MD, FACAAI
John B. Hagan, MD, FACAAI
Jeremy S. Katcher, MD, FACAAI
Andrew A. White, MD, FACAAI
Mandel R. Sher, MD, FACAAI
Annette F. Carlisle, MD  
Ryan B. Israelsen, MD  
Matthew Greenhawt, MD, MBA, MSc, FACAAI  
Douglas P. Mack, MD, MSc  
Aikaterini Anagnostou, MD, PhD, FACAAI
Kelly M. Maples, MD, FACAAI  
Catherine Hammond, MD  
Brian T. Kelly, MD, MA, FACAAI  
Nicole M. Chase, MD, FAAP, FACAAI  
Jennifer Chen Li, MD  
Sarbjit Singh Saini, MD  
David A Khan, MD, FACAAI  
Melanie Dispenza, MD, PhD
Mark Boguniewicz, MD, FACAAI  
Derek K. Chu, MD, PhD  
Peck Y. Ong, MD, FACAAI

Available Credit

  • 11.00 AMA PRA Category 1 Credit™
  • 11.00 Attendance
  • 11.00 CBRN
Please login or create an account to take this course.